Tag: KDC-MN-1495

  • Boswellic-Acid

    Pentacyclic triterpenic acid from Boswellia serrata oleogum resin with selective 5-lipoxygenase inhibition and pleiotropic anti-inflammatory activity

    A family of ursane- and oleanane-type pentacyclic triterpenes isolated from Boswellia serrata frankincense resin, distinguished by noncompetitive allosteric inhibition of 5-lipoxygenase and convergent anti-inflammatory activity through NF-kappaB suppression, topoisomerase inhibition, and leukotriene biosynthesis blockade.

    Abstract

    Boswellic acids are a family of pentacyclic triterpenic acids isolated from the oleogum resin (frankincense) of Boswellia serrata and related species (B. carterii, B. sacra, B. papyrifera) that have been used in Ayurvedic medicine for centuries under the name Salai guggal and are now recognized as pharmacologically active anti-inflammatory agents with a distinct mechanism of action centered on selective, noncompetitive, allosteric inhibition of 5-lipoxygenase (5-LOX). The family comprises four principal bioactive congeners: beta-boswellic acid (beta-BA), 11-keto-beta-boswellic acid (KBA), 3-O-acetyl-beta-boswellic acid (ABA), and 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), with AKBA representing the most potent 5-LOX inhibitor (IC50 approximately 1.5 micromolar in human neutrophils) and the primary pharmacologically characterized congener. The 5-LOX inhibition by AKBA proceeds through an allosteric, nonredox, noncompetitive mechanism that is unique among clinically studied leukotriene synthesis inhibitors and distinguishes the boswellic acid class from both the redox-type 5-LOX inhibitors (zileuton) and the competitive cysteinyl leukotriene receptor antagonists (montelukast, zafirlukast). Beyond 5-LOX inhibition, boswellic acids exert convergent anti-inflammatory activity through suppression of NF-kappaB signaling via direct inhibition of IkappaB kinases (IKKalpha and IKKbeta), inhibition of human leukocyte elastase, inhibition of topoisomerases I and IIalpha, modulation of complement system activation, and suppression of proinflammatory cytokine release including tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6. Pharmacokinetics in humans are characterized by poor oral bioavailability of the keto-boswellic acids (KBA and AKBA) attributable to extensive first-pass hepatic metabolism via CYP3A4-mediated hydroxylation and carboxylesterase 2-mediated deacetylation, with plasma elimination half-lives of approximately 6 hours. Concomitant administration with a lipid-rich meal substantially improves absorption. The compound class is generally well tolerated, with the principal adverse events being mild gastrointestinal discomfort (nausea, acid reflux, diarrhea) and rare allergic dermatitis. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.